ClinicalTrials.gg
RecruitingNCT07645066PSB-AFUpdated Sep 23, 2026

Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction

An interventional study of RAA pacing and PSB pacing in Pacing Therapy and Cardiac Pacing, sponsored by Shanghai Tong Ren Hospital. Recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Shanghai Tong Ren Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.

Read the detailed description

Sinus node dysfunction (SND) is a common indication for permanent pacemaker implantation. Conventional right atrial appendage (RAA) pacing may result in delayed or dyssynchronous atrial activation, potentially increasing the risk of atrial arrhythmias. Posterosuperior bundle (PSB) pacing is a novel physiological atrial pacing approach. This study is a prospective, multicenter, open-label, randomized controlled trial. A total of approximately 300 eligible SND patients indicated for pacemaker implantation will be enrolled and randomly assigned (1:1) to PSB pacing or RAA pacing. Ventricular pacing will be performed using left bundle branch area pacing in both groups. Following implantation, the pacemaker will be programmed in DDD mode with a lower rate of 70 beats/min during daytime and 60 beats/min during nighttime. Rate-responsive pacing will be enabled by default when available; ATP will be disabled by default. Participants will be followed at 3, 6, 12, and 24 months after implantation. The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes. Secondary endpoints include atrial high-rate episodes, AF burden, pacing parameters, ECG and echocardiographic indices, laboratory findings, and mortality outcomes. Safety endpoints include procedural complications and device-related adverse events.

02

Conditions studied

  • Pacing Therapy
  • Cardiac Pacing

Keywords

  • Posterosuperior bundle pacing
  • Right atrial appendage pacing
  • Physiological pacing
  • atrial pacing
03

In context

Lead sponsor

Shanghai Tong Ren Hospital is the lead sponsor of 17 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Indication for permanent pacemaker implantation, including:
  • Sinus node dysfunction, defined as at least one of the following:
  • Symptomatic sinus bradycardia
  • Tachy-brady syndrome
  • Chronotropic incompetence
  • Sinus pause / arrest
  • Atrioventricular block (if present); if ventricular pacing is required, left bundle branch area pacing is planned
  • Expected survival >1 year
  • Panned implantation of a device capable of detecting atrial high-rate episodes
  • Willing and able to provide

Exclusion criteria

Exclusion Criteria:

  • Persistent atrial fibrillation (AF) (>7 days), long-standing persistent AF, permanent AF, or prior atrioventricular node ablation
  • Prior cardiac implantable electronic device (CIED) requiring replacement, upgrade, or revision
  • Indication for cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT-D)
  • Prior cardiac surgery, severe hepatic or renal dysfunction, or other life-threatening systemic diseases
  • Acute myocardial infarction within 3 months before enrollment
  • Persistent left superior vena cava or dextrocardia
  • Pregnant or breastfeeding women, or women of not using effective
  • Participation in another clinical trial that may interfere
  • Any condition that, in the opinion of the investigator, makes participation unsuitable
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    PSB pacing

    Patients were randomly assigned to receive posterosuperior bundle pacing for atrial pacing during regular pacemaker implantation procedures.

    Procedure: PSB pacing

  • Active comparator
    RAA pacing

    Patients were randomly assigned to receive right atrial appendage pacing for atrial pacing during regular pacemaker implantation procedures.

    Procedure: RAA pacing

Interventions

  • ProcedureRAA pacing

    Atrial pacing lead implanted at the right atrial appendage. Left bundle branch area pacing will be applied if ventricular pacing is necessary.

  • ProcedurePSB pacing

    Atrial pacing lead implanted at the posterosuperior bundle region. Left bundle branch area pacing will be applied if ventricular pacing is necessary.

06

What researchers measure

Primary outcomes

  1. Incidence of atrial fibrillation

    Incidence of atrial fibrillation ≥ 6 minutes during follow-ups

    Time frame: From implantation to regular follow-ups up to 24 months

Secondary outcomes

  1. Atrial high-rate episodes

    Time frame: From implantation to regular follow-ups up to 24 months

  2. AF burden

    Time frame: From implantation to regular follow-ups up to 24 months

  3. Intrinsic P-wave duration

    Measured from the onset of the P wave to the end

    Time frame: At baseline and regular follow-ups up to 24 months, when intrinsic atrial rhythm is assessable

  4. Paced P-wave duration

    Measured from the pacing stimulus to P wave end duration

    Time frame: From implantation to regular follow-ups up to 24 months

  5. Left ventricular ejection fraction (LVEF)

    Standard transthoracic echocardiographic parameter

    Time frame: At baseline, 6-, 12-, and 24-month follow-ups

  6. Left atrial diameter (LAD)

    Standard transthoracic echocardiographic parameter

    Time frame: At baseline, 6-, 12-, and 24-month follow-ups

  7. Right atrial diameter (RAD)

    Standard transthoracic echocardiographic parameter

    Time frame: At baseline, 6-, 12-, and 24-month follow-ups

  8. Left ventricular end-systolic diameter (LVESD)

    Standard transthoracic echocardiographic parameter

    Time frame: At baseline, 6-, 12-, and 24-month follow-ups

  9. Left ventricular end-diastolic diameter (LVEDD)

    Standard transthoracic echocardiographic parameter

    Time frame: At baseline, 6-, 12-, and 24-month follow-ups

  10. E/e'

    Standard transthoracic echocardiographic parameter

    Time frame: At baseline, 6-, 12- , 24-month follow-ups

  11. Mitral regurgitation severity

    Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe)

    Time frame: At baseline, 6-, 12- , 24-month follow ups

  12. Tricuspid regurgitation severity

    Standard transthoracic echocardiographic measurement using standard semi-quantitative grading (none/trace, mild, moderate, or severe)

    Time frame: At baseline, 6-, 12-, 24- month follow-ups

  13. NT-pro BNP

    Standard transthoracic echocardiographic parameter

    Time frame: At baseline, before discharge, and 6-month follow-up

  14. eGFR

    Time frame: At baseline, before discharge, and 6 - month follow-up

  15. All-cause mortality

    Time frame: From implantation to regular follow-ups up to 24 months

  16. Cardiovascular death

    Time frame: From implantation to regular follow-ups up to 24 months

Other outcomes

  1. Procedural complications

    Safety Outcome

    Time frame: Perioperative

  2. Postoperative adverse events

    Safety Outcome, including lead-related complications, thromboembolic events, etc.

    Time frame: From implantation to regular follow-ups up to 24 months

  3. Atrial pacing capture threshold

    Time frame: From implantation to regular follow-ups up to 24 months

  4. Atrial sensing amplitude

    Time frame: From implantation to regular follow-ups up to 24 months

  5. Atrial pacing output

    Time frame: From implantation to regular follow-ups up to 24 months

  6. Paced P-wave morphology

    positive, negative, notched, and biphasic

    Time frame: From implantation to regular follow-ups up to 24 months

  7. Intrinsic P-wave morphology

    positive, negative, notched, and biphasic

    Time frame: At baseline, implant, and regular follow-ups up to 24 months when intrinsic atrial rhythm is assessable

07

Study locations

1 of 10 sites recruiting
  • China Medical University affiliated AnQing Municipal Hospital
    Anqing, Anhui, China
    Not yet recruiting
  • Tongling People's Hospital
    Tongling, Anhui, China
    Not yet recruiting
  • Affiliated Hospital of Zunyi Medical College
    Zunyi, Guizhou, China
    Not yet recruiting
  • Wuhan Asia General Hospital
    Wuhan, Hubei, China
    Not yet recruiting
  • Tong Ren Hospital, Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200336, China
    Recruiting
  • Fudan University affiliated Huadong Hospital
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
  • Shanghai Jiaotong University affiliated Shanghai Ninth People's Hospital
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
  • Shanghai Jiaotong University affiliated Shanghai Sixth People's Hospital
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
  • Shanghai University of Traditional Chinese Medicine affiliated Putuo Hospital
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
  • Tongji University School of Medicine affiliated Tongji University
    Shanghai, Shanghai Municipality, China
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Feb 2029, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jun 12, 2026
StartActual
Aug 25, 2026
Primary completionEst.
Feb 1, 2029
CompletionEst.
Feb 1, 2029
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07645066
Lead sponsor
Shanghai Tong Ren Hospital
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Aug 25, 2026
Primary completion
Feb 1, 2029 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Sep 23, 2026

Study contacts

Zhaohui Qiu
Contact
qzh3503@shtrhospital.com
+862152039999

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion